# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION MEMORANDUM

A. 510(k) Number: K172713   
B. Purpose for Submission: To obtain a substantial equivalence determination for the Lumipulse G B•R•A•H•M•S PCT Immunoreaction Cartridges, Lumipulse G B•R•A•H•M•S PCT Calibrators set   
C. Measurand: Procalcitonin (PCT)   
D. Type of Test: Chemiluminescent Enzyme Immunoassay (CLEIA)   
E. Applicant: Fujirebio Diagnostics, Inc. (FDI)   
F. Proprietary and Established Names: Lumipulse G B•R•A•H•M•S PCT Immunoreaction Cartridges, Lumipulse G B•R•A•H•M•S PCT Calibrators set   
G. Regulatory Information: 1. Regulation section: 21 CFR 866.3215; Device to detect and measure non-microbial analyte(s) in human clinical specimens to aid in assessment of patients with suspected sepsis 2. Classification:

Class II (Special Controls)

3. Product codes: PRI, PMT, NTM

4. Panel: 83 - (Microbiology)

# H. Intended Use:

1. Intended use(s): See Indications for Use.

2. Indication(s) for use:

Lumipulse G B•R•A•H•M•S PCT Immunoreaction Cartridges:

The Lumipulse G B•R•A•H•M•S PCT is a Chemiluminescent Enzyme Immunoassay (CLEIA) for the quantitative determination of PCT (procalcitonin) in human serum and plasma (sodium heparin, lithium heparin, sodium citrate or dipotassium EDTA) on the LUMIPULSE G System.

Used in conjunction with other laboratory findings and clinical assessments, Lumipulse G B•R•A•H•M•S PCT is intended for use as an:

· Aid in the risk assessment of critically ill patients on their first day of intensive care unit (ICU) admission for progression to severe sepsis and septic shock. Aid in assessing the cumulative 28-day risk of all-cause mortality for patients diagnosed with severe sepsis or septic shock in the ICU or when obtained in the emergency department or other medical wards prior to ICU admission, using a change in PCT level over time.   
· Aid in decision making on antibiotic therapy for patients with suspected or confirmed lower respiratory tract infections (LRTI) – defined as community acquired pneumonia (CAP), acute bronchitis, and acute exacerbation of chronic obstructive pulmonary disease (AECOPD) – in an inpatient setting or an emergency department. Aid in decision making on antibiotic discontinuation for patients with suspected or confirmed sepsis.

# Lumipulse G B∙R∙A∙H∙M∙S PCT Calibrators set

Lumipulse G B∙R∙A∙H∙M∙S PCT Calibrators set is for in vitro diagnostic use in the calibration of Lumipulse G B∙R∙A∙H∙M∙S PCT on the LUMIPULSE G System.

3. Special conditions for use statement(s): For prescription use.

4. Special instrument requirements: All data were generated using the LUMIPULSE G1200 System.

# I. Device Description:

Lumipulse G B•R•A•H•M•S PCT is an assay system, including a set of immunoassay reagents, for the quantitative measurement of PCT in specimens based on CLEIA technology by a two-step sandwich immunoassay method on the LUMIPULSE G1200 System.

The Lumipulse G B•R•A•H•M•S PCT Immunoreaction Cartridges (IC) consists of $3 \times 1 4$ tests.

Each kit contains the following:

Antibody-Coated Particle Solution   
(Liquid when used, $2 5 0 \mu \mathrm { L } / .$ Immunoreaction Cartridge)   
Contains $1 5 0 ~ \mu \mathrm { g / m L }$ anti-PCT monoclonal antibody (mouse) and anti-calcitonin monoclonal antibody (mouse) coated particles, protein stabilizers (bovine and mouse) and chemical stabilizers in $0 . 1 5 { \mathrm { M } }$ sodium chloride/Tris buffer. This solution contains gelatin and turns into gel at $1 5 \mathrm { { ^ \circ C } }$ or lower.   
Preservative: Sodium azide Enzyme-Labeled Antibody Solution   
(Liquid; $3 5 0 ~ \mu \mathrm { L / I m r }$ munoreaction Cartridge)   
Contains $0 . 2 5 ~ \mu \mathrm { g / m L }$ alkaline phosphatase (ALP: calf)-labeled anti-katacalcin monoclonal antibody (mouse), protein stabilizers (bovine, calf and mouse) and chemical stabilizers in $0 . 1 { \mathrm { ~ M ~ } }$ sodium chloride/MES buffer.   
Preservative: Sodium azide

Lumipulse G B•R•A•H•M•S PCT Calibrators set CAL SET 234150, Lyophilized, $2 \times 2$

Each calibrator kit contains one bottle each of Calibrators 1, 2, and Reconstituting Solution. These calibrators are lyophilized and are prepared by adding exactly $0 . 5 \mathrm { m L }$ of Reconstituting Solution to each lyophilized calibrator. The calibrator kit is packaged separately.

CAL $1 \colon 0 \mathrm { n g / m L }$ PCT calibrator $2 \times 0 . 5 \mathrm { m L / v i a l } )$ )   
CAL 2: $1 0 0 ~ \mathrm { { n g / m L } }$ PCT calibrator $( 2 \times 0 . 5 \mathrm { m L / v i a l } )$ ; Contains procalcitonin in $0 . 1 5 { \mathrm { M } }$ sodium chloride in Tris buffer with protein stabilizer (bovine).   
Preservative: ProClin 300.   
RS Reconstituting Solution: Liquid, $1 \times 1 0 ~ \mathrm { m L }$   
Preservative: Sodium azide

Materials Required - Not Provided:

Control materials: Controls are not provided   
NOTE: Lumipulse G B•R•A•H•M•S PCT Package insert indicates ‘Use control materials with at least two levels (e.g. low and high)’   
Premarket studies used three Thermo Scientific MAS Omni•CARDIOControls (k122291). o Level 1: 0.22 to $0 . 4 2 ~ \mathrm { { n g / m L } }$   
o Level 2: 1.49 to $2 . 7 7 \mathrm { n g / m L }$   
o Level 3: 6.81 to $1 2 . 6 5 ~ \mathrm { n g / m L }$   
Purified water   
Micropipettes   
Recommended sample cups; refer to the LUMIPULSE G System Operation Manual.

# J. Substantial Equivalence Information:

1. Predicate device name(s): B•R•A•H•M•S PCT sensitive KRYPTOR

2. Predicate 510(k) number(s): K171338

3. Comparison with predicate:

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">DeviceLumipulse GB·R•A·H·M•S PCTK172713</td><td colspan="1" rowspan="1">PredicateB•R•A•H•M•S PCT sensitiveKRYPTORK171338</td></tr><tr><td colspan="1" rowspan="1">Device Type</td><td colspan="1" rowspan="1">In vitro diagnostic</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Classification</td><td colspan="1" rowspan="1">Class II</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Analyte</td><td colspan="1" rowspan="1">Procalcitonin</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Regulation</td><td colspan="1" rowspan="1">21CFR § 866.3215;Device to detect and measurenonmicrobial analyte(s) in humanclinical specimens to aid in assessmentof patients with suspected sepsis</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">SpecimenCollectionMethod</td><td colspan="1" rowspan="1">Routine PhlebotomyTechniques</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Indications forUse</td><td colspan="1" rowspan="1">The Lumipulse G B•R•A•H•M·S PCT isa Chemiluminescent EnzymeImmunoassay (CLEIA) for thequantitative determination of PCT(procalcitonin) in human serum andplasma (sodium heparin, lithium heparin,sodium citrate or dipotassium EDTA) onthe LUMIPULSE G System.Used in conjunction with otherlaboratory findings and clinicalassessments, Lumipulse GB•R•A•H•M•S PCT is intended for useas an:Aid in the risk assessment of criticallyill patients on their first day of intensivecare unit (ICU) admission forprogression to severe sepsis and septicshock.Aid in assessing the cumulative 28-dayrisk of all-cause mortality for patients</td><td colspan="1" rowspan="1">The B·R.A·H·M·S PCT sensitiveKRYPTOR is an immunofluorescentassay using Time-Resolved AmplifiedCryptate Emission (TRACE)technology to determine theconcentration of PCT (procalcitonin) inhuman serum and EDTA or heparinplasma. The B·R·A·H·M.S PCTsensitive KRYPTOR is intended to beperformed on the B·R·A·H·M.SKRYPTOR analyzer family. Used inconjunction with other laboratoryfindings and clinical assessments.B·R·A·H·M.S PCT sensitiveKRYPTOR is intended for use asfollows:• to aid in the risk assessment ofcritically ill patients on their first day ofICU admission for progression to severesepsis and septic shock,• to determine the change in PCT level</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">diagnosed with severe sepsis or septicshock in the ICU or when obtained in theemergency department or other medicalwards prior to ICU admission, using achange in PCT level over time.•Aid in decision making on antibiotictherapy for patients with suspected orconfirmed lower respiratory tractinfections (LRTI)  defined ascommunity acquired pneumonia (CAP),acute bronchitis, and acute exacerbationof chronic obstructive pulmonary disease(AECOPD)  in an inpatient setting or anemergency department.• Aid in decision making on antibioticdiscontinuation for patients withsuspected or confirmed sepsis.</td><td colspan="1" rowspan="1">over time as an aid in assessing thecumulative 28-day risk of all-causemortality for patients diagnosed withsevere sepsis or septic shock in the ICUor when obtained in the emergencydepartment or other medical wards priorto ICU admission,• to aid in decision making on antibiotictherapy, for inpatients or patients in theemergency department with suspectedor confirmed lower respiratory tractinfections (LRTI) defined ascommunity-acquired pneumonia (CAP),acute bronchitis, and acute exacerbationof chronic obstructive pulmonarydisease (AECOPD),• to aid in decision making on antibioticdiscontinuation for patients withsuspected or confirmed sepsis.</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>DeviceLumipulse GB•R•A·H•M•S PCTK172713</td><td rowspan=1 colspan=1>PredicateB•R•A•H·M•S PCT sensitiveKRYPTORK171338</td></tr><tr><td rowspan=1 colspan=1>Principle ofOperation</td><td rowspan=1 colspan=1>Automated QuantitativeChemiluminescent EnzymeImmunoassay (CLEIA)</td><td rowspan=1 colspan=1>Time-Resolved AmplifiedCryptate Emission (TRACE)</td></tr><tr><td rowspan=1 colspan=1>InstrumentSystem</td><td rowspan=1 colspan=1>LUMIPULSE G System</td><td rowspan=1 colspan=1>BRAHMS KRYPTORanalyzer</td></tr><tr><td rowspan=1 colspan=1>Assay Type</td><td rowspan=1 colspan=1>Two-step sandwichimmunoassay based onchemiluminescenttechnology</td><td rowspan=1 colspan=1>Immunofluorescent assay</td></tr><tr><td rowspan=1 colspan=1>Type ofSpecimen</td><td rowspan=1 colspan=1>Human serum and plasma(sodium heparin, lithiumheparin, sodium citrate ordipotassium EDTA)</td><td rowspan=1 colspan=1>Human serum and plasma(EDTA, heparin)</td></tr><tr><td rowspan=1 colspan=1>Assay Range</td><td rowspan=1 colspan=1>0.020 - 100 ng/mL</td><td rowspan=1 colspan=1>0.02-5000ng/mL</td></tr><tr><td rowspan=1 colspan=1>SampleVolume</td><td rowspan=1 colspan=1>60 μl</td><td rowspan=1 colspan=1>50μl</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

· CLSI EP5-A3 - Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline - Third Edition CLSI EP7-A2 - Interference Testing in Clinical Chemistry; Approved Guideline-Second Edition CLSI EP28-A3c - Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline-Third Edition CLSI EP17-A2 - Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline Second Edition CLSI EP6-A - Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline CLSI EP9-A3 – Measurement Procedure Comparison and Bias Estimation Using Patient Samples; approved Guideline – Third Edition CLSI EP25-A – Evaluation of Stability of In Vitro Diagnostic Reagents: Approved Guideline Guidance on Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not Individually Identifiable - Guidance for Sponsors, Institutional Review Boards, Clinical Investigators and FDA Staff Test Principle: Guidance for Industry and Food and Drug Administration Staff eCopy Program for Medical Device Submissions (December 31, 2012) Guidance for Industry and Food and Drug Administration Staff - Refuse to Accept Policy for 510(k)s (August 4, 2015)

# L. Test Principle:

Lumipulse G B•R•A•H•M•S PCT is an assay system, including a set of immunoassay reagents, for the quantitative measurement of PCT in specimens based on CLEIA technology by a two- step sandwich immunoassay method on the LUMIPULSE G1200 System. PCT in specimens specifically binds to antiPCT monoclonal antibody (mouse) and anti-calcitonin monoclonal antibody (mouse) on the particles, and antigen-antibody immunocomplexes are formed. The particles are washed and rinsed to remove unbound materials. Alkaline phosphatase (ALP; calf)-labeled anti-katacalcin monoclonal antibody (mouse) specifically binds to PCT of the immunocomplexes on the particles, and additional immunocomplexes are formed. The particles are washed and rinsed to remove unbound materials. Substrate Solution is added and mixed with the particles. AMPPD (3- $2 ^ { \circ }$ -Spiroadamantane)-4- Methoxy-4-( $3 ^ { \circ }$ -Phosphoryloxy) Phenyl- 1, 2-Dioxetane Disodium Salt) contained in the Substrate Solution is dephosphorylated by the catalysis of ALP indirectly conjugated to particles. Luminescence (at a maximum wavelength of $4 7 7 \mathrm { n m }$ ) is generated by the cleavage reaction of dephosphorylated AMPPD. The luminescent signal reflects the amount of PCT.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Prior to the precision study, technicians were required to pass a 3-day (Lot A and B) and 1-day (Lot D) Familiarization Study to demonstrate proficiency on Lumipulse G PCT.

Eight panels (five native serum and three recombinant) were tested in duplicate. Thermo Scientific MAS Omni•CARDIO Controls were also tested for validity and precision. The results of the 20-day precision calculations for Lumipulse G B•R•A•H•M•S PCT performed at

Fujirebio Diagnostics, Inc are shown below:

· Lot A Immunoreaction Cartridges (ICs)/Lot A Calibrators for Control Levels 1-3 and Panels 1-6   
· Lot D ICs/Lot D Calibrators for Panels 7 and 8

The analyses determined the CV for the within laboratory precision of the Lumipulse G B•R•A•H•M•S PCT for the eight (8) panels CV ranged from $1 . 8 \%$ to $3 . 1 \%$ . The CV for the within laboratory precision of the Lumipulse G B•R•A•H•M•S PCT for the three (3) controls ranged from $3 . 3 \%$ to $4 . 7 \%$ . The precision of all controls and panels for the 20-day Precision Study met the acceptance criteria of a $C V \leq 1 0 \%$ . The results of the 20-day precision calculations for Lumipulse G B•R•A•H•M•S PCT are shown in Table 1 below:

Table 1: Summary for FDI 20-day Precision $\scriptstyle \mathrm { n = 8 0 }$ for each sample) for Lot A (Controls and Panels 1-6) and Lot D (Panels 7 and 8)   

<table><tr><td rowspan=1 colspan=2>cYanmaGYellowb</td><td rowspan=1 colspan=2>Within-Run(Repeatability)</td><td rowspan=1 colspan=2>Between Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Within-Laboratory (Total)</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(ng/mL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Control Level 1</td><td rowspan=1 colspan=1>0.662</td><td rowspan=1 colspan=1>0.010</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.026</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>0.014</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.031</td><td rowspan=1 colspan=1>4.7</td></tr><tr><td rowspan=1 colspan=1>Control Level 2</td><td rowspan=1 colspan=1>3.911</td><td rowspan=1 colspan=1>0.045</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.129</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>0.026</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.139</td><td rowspan=1 colspan=1>3.6</td></tr><tr><td rowspan=1 colspan=1>Control Level 3</td><td rowspan=1 colspan=1>14.978</td><td rowspan=1 colspan=1>0.163</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.393</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>0.245</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.490</td><td rowspan=1 colspan=1>3.3</td></tr><tr><td rowspan=1 colspan=1>Panel 1</td><td rowspan=1 colspan=1>0.300</td><td rowspan=1 colspan=1>0.005</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.004</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.003</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.007</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=1 colspan=1>Panel 2</td><td rowspan=1 colspan=1>2.219</td><td rowspan=1 colspan=1>0.032</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.016</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.027</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.045</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>Panel 3</td><td rowspan=1 colspan=1>12.323</td><td rowspan=1 colspan=1>0.129</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.144</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.098</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.217</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>Panel 4</td><td rowspan=1 colspan=1>36.217</td><td rowspan=1 colspan=1>0.379</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.308</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.445</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.661</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>Panel 5</td><td rowspan=1 colspan=1>54.132</td><td rowspan=1 colspan=1>0.596</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.529</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.642</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.024</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>Panel 6</td><td rowspan=1 colspan=1>80.361</td><td rowspan=1 colspan=1>1.265</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.879</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.632</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.666</td><td rowspan=1 colspan=1>2.1</td></tr><tr><td rowspan=1 colspan=1>Panel 7</td><td rowspan=1 colspan=1>0.112</td><td rowspan=1 colspan=1>0.002</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>0.002</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>0.001</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.004</td><td rowspan=1 colspan=1>3.1</td></tr><tr><td rowspan=1 colspan=1>Panel 8</td><td rowspan=1 colspan=1>0.534</td><td rowspan=1 colspan=1>0.010</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.003</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.013</td><td rowspan=1 colspan=1>2.5</td></tr></table>

# Lot-To-Lot Reproducibility for Combined Data

The precision analyses for the combined lot-to-lot analysis for Lots A, B and C determined the CV for the within laboratory reproducibility for Lumipulse G B•R•A•H•M•S PCT to be $\leq 5 . 3 \%$ in this study. The CV for the within laboratory reproducibility for Lumipulse G B•R•A•H•M•S PCT was determined to be $\leq 3 . 0 \%$ for the panels 1-6. The CV for the within laboratory reproducibility for Lumipulse G B•R•A•H•M•S PCT was determined to be $\leq 5 . 3 \%$ for the three (3) controls. The CV for the within laboratory reproducibility of Lumipulse G B•R•A•H•M•S PCT ranged from $1 . 8 \%$ to $5 . 3 \%$ . The CV for the between-lot reproducibility for Lumipulse G B•R•A•H•M•S PCT was $\leq 6 . 5 \%$ . See Table 2 below.

Table 2: Summary of the Lot-to-Lot Reproducibility for the Combined Data for Lots A, B, C $\mathrm { \Pi } ^ { \mathrm { - } 1 2 0 }$ for each sample)   

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Between Lots</td><td rowspan=1 colspan=2>Between Day</td><td rowspan=1 colspan=2>Between Run</td><td rowspan=1 colspan=2>Within Runs(Repeatability)</td><td rowspan=1 colspan=2>Within-Laboratory(Total)</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(ng/L)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Control Level 1</td><td rowspan=1 colspan=1>0.634</td><td rowspan=1 colspan=1>0.030</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>0.013</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>0.030</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>0.009</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.033</td><td rowspan=1 colspan=1>5.3</td></tr><tr><td rowspan=1 colspan=1>Control Level 2</td><td rowspan=1 colspan=1>3.816</td><td rowspan=1 colspan=1>0.137</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>0.016</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.127</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>0.055</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.139</td><td rowspan=1 colspan=1>3.7</td></tr><tr><td rowspan=1 colspan=1>Control Level 3</td><td rowspan=1 colspan=1>14.875</td><td rowspan=1 colspan=1>0.313</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.141</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.434</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>0.164</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.487</td><td rowspan=1 colspan=1>3.3</td></tr><tr><td rowspan=1 colspan=1>Panel 1</td><td rowspan=1 colspan=1>0.290</td><td rowspan=1 colspan=1>0.012</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>0.004</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.006</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>0.005</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.009</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=1 colspan=1>Panel 2</td><td rowspan=1 colspan=1>2.163</td><td rowspan=1 colspan=1>0.075</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>0.021</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.038</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.026</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.048</td><td rowspan=1 colspan=1>2.2</td></tr><tr><td rowspan=1 colspan=1>Panel 3</td><td rowspan=1 colspan=1>12.332</td><td rowspan=1 colspan=1>0.320</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>0.221</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.133</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.122</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.280</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=1 colspan=1>Panel 4</td><td rowspan=1 colspan=1>38.147</td><td rowspan=1 colspan=1>2.280</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>0.363</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.467</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.367</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.701</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>Panel 5</td><td rowspan=1 colspan=1>57.114</td><td rowspan=1 colspan=1>3.392</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>0.856</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.625</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.674</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.248</td><td rowspan=1 colspan=1>2.2</td></tr><tr><td rowspan=1 colspan=1>Panel 6</td><td rowspan=1 colspan=1>86.233</td><td rowspan=1 colspan=1>5.585</td><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>1.018</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.138</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.489</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>2.141</td><td rowspan=1 colspan=1>2.5</td></tr></table>

# Site to Site Reproducibility for Combined Data

The reproducibility analyses for the combined site-to-site analysis for Lot A determined the CV for the total reproducibility for Lumipulse G B•R•A•H•M•S PCT to be $\leq 4 . 9 \%$ in this study. The CV for the reproducibility for Lumipulse G B•R•A•H•M•S PCT was determined to be $\leq$ $4 . 8 \%$ for the six (6) panels. The CV for the reproducibility for Lumipulse G B•R•A•H•M•S PCT was determined to be $\leq 4 . 9 \%$ for the three (3) controls. The CV for the reproducibility of Lumipulse G B•R•A•H•M•S PCT ranged from $2 . 9 \%$ to $4 . 9 \%$ . The CV for the between site reproducibility for Lumipulse G B•R•A•H•M•S PCT was $\leq 4 . 7 \%$ . Results are summarized in Table 3 below.

Table 3: Summary of the Site-to-Site Reproducibility for the Combined Data for Lot A $\mathrm { \ m } { = } 1 2 0$ for each panel)   

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Between Sites</td><td rowspan=1 colspan=2>Between Days</td><td rowspan=1 colspan=2>Between Runs</td><td rowspan=1 colspan=2>Within Runs(Repeatability)</td><td rowspan=1 colspan=2>Reproducibility(Total)</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(ng/mL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Control Level 1</td><td rowspan=1 colspan=1>0.647</td><td rowspan=1 colspan=1>0.019</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>0.023</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>0.020</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>0.012</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>0.032</td><td rowspan=1 colspan=1>4.9%</td></tr><tr><td rowspan=1 colspan=1>Control Level 2</td><td rowspan=1 colspan=1>3.872</td><td rowspan=1 colspan=1>0.077</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>0.109</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>0.096</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>0.054</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>0.149</td><td rowspan=1 colspan=1>3.8%</td></tr><tr><td rowspan=1 colspan=1>Control Level 3</td><td rowspan=1 colspan=1>15.062</td><td rowspan=1 colspan=1>0.085</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>0.337</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>0.312</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>0.166</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>0.481</td><td rowspan=1 colspan=1>3.2%</td></tr><tr><td rowspan=1 colspan=1>Panel 1</td><td rowspan=1 colspan=1>0.291</td><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>0.010</td><td rowspan=1 colspan=1>3.6%</td><td rowspan=1 colspan=1>0.005</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>0.014</td><td rowspan=1 colspan=1>4.8%</td></tr><tr><td rowspan=1 colspan=1>Panel 2</td><td rowspan=1 colspan=1>2.170</td><td rowspan=1 colspan=1>0.033</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>0.049</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>0.061</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>0.032</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>0.075</td><td rowspan=1 colspan=1>3.5%</td></tr><tr><td rowspan=1 colspan=1>Panel 3</td><td rowspan=1 colspan=1>12.297</td><td rowspan=1 colspan=1>0.375</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>0.222</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>0.417</td><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>0.170</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>0.485</td><td rowspan=1 colspan=1>3.9%</td></tr><tr><td rowspan=1 colspan=1>Panel 4</td><td rowspan=1 colspan=1>37.074</td><td rowspan=1 colspan=1>1.303</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>0.586</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>1.182</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>0.361</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>1.354</td><td rowspan=1 colspan=1>3.6%</td></tr><tr><td rowspan=1 colspan=1>Panel 5</td><td rowspan=1 colspan=1>55.428</td><td rowspan=1 colspan=1>2.043</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>1.144</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>1.385</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>0.613</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>1.846</td><td rowspan=1 colspan=1>3.3%</td></tr><tr><td rowspan=1 colspan=1>Panel 6</td><td rowspan=1 colspan=1>82.850</td><td rowspan=1 colspan=1>3.868</td><td rowspan=1 colspan=1>4.7%</td><td rowspan=1 colspan=1>1.006</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>1.719</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>1.285</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>2.365</td><td rowspan=1 colspan=1>2.9%</td></tr></table>

# b. Linearity/assay reportable range:

Dilutions targeted the top of the measurement range of the Lumipulse G B•R•A•H•M•S PCT assay $( { \sim } 1 2 0 ~ \mathrm { { n g / m L } ) }$ and went below the LOQ $( < 0 . 0 2 0 \mathrm { n g / m L } )$ . Eleven separate dilutions of the High Serum Pool (HSP) by the Low Serum Pool (LSP) were prepared. Undiluted High and Low serum pools were tested as sample 1 and sample 13 in the dilution series Lumipulse G

B•R•A•H•M•S PCT on the LUMIPULSE G1200 System demonstrated linearity in a study consistent with the guidelines in the CLSI Protocol EP6-A.9) High and low sample pools were created using patient serum samples that contained naturally expressed PCT. Lumipulse G B•R•A•H•M•S PCT assay was shown to be linear within the actual test results of $0 . 0 1 0 ~ \mathrm { { n g / m L } }$ to $1 0 4 . 2 6 0 \mathrm { n g / m L }$ and supports the claimed Lumipulse G B•R•A•H•M•S PCT measurement range of $0 . 0 2 0 \ \mathrm { n g / m L } - 1 0 0 . 0 0 0 \ \mathrm { n g / m L }$ . Results are summarized in Table 4 below.

Table 4: Linearity   

<table><tr><td rowspan=1 colspan=1>Dilution</td><td rowspan=1 colspan=1>Target value(ng/mL)</td><td rowspan=1 colspan=1>Mean measuredvalue (ng/mL)</td><td rowspan=1 colspan=1>SD(ng/mL)</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>104.260*</td><td rowspan=1 colspan=1>2.990</td><td rowspan=1 colspan=1>2.9</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>86.680</td><td rowspan=1 colspan=1>0.529</td><td rowspan=1 colspan=1>0.6</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>70.449</td><td rowspan=1 colspan=1>0.693</td><td rowspan=1 colspan=1>1.0</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>53.370</td><td rowspan=1 colspan=1>0.347</td><td rowspan=1 colspan=1>0.7</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>35.961</td><td rowspan=1 colspan=1>0.100</td><td rowspan=1 colspan=1>0.3</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>17.555</td><td rowspan=1 colspan=1>0.617</td><td rowspan=1 colspan=1>3.5</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>8.015</td><td rowspan=1 colspan=1>0.125</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>4.087</td><td rowspan=1 colspan=1>0.085</td><td rowspan=1 colspan=1>2.1</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1.613</td><td rowspan=1 colspan=1>0.011</td><td rowspan=1 colspan=1>0.7</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0.481</td><td rowspan=1 colspan=1>0.424</td><td rowspan=1 colspan=1>0.009</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0.241</td><td rowspan=1 colspan=1>0.228</td><td rowspan=1 colspan=1>0.002</td><td rowspan=1 colspan=1>0.8</td></tr><tr><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0.121</td><td rowspan=1 colspan=1>0.111</td><td rowspan=1 colspan=1>0.001</td><td rowspan=1 colspan=1>1.3</td></tr><tr><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>0.001</td><td rowspan=1 colspan=1>0.010</td><td rowspan=1 colspan=1>0.001</td><td rowspan=1 colspan=1>6.1</td></tr></table>

The statistical evaluation of linearity was determined using EP6-A. Linear, quadratic and cubic regressions were fitted. Lumipulse G B•R•A•H•M•S PCT correlated with expected concentrations according to the linear regression formula: $y = 0 . 0 0 8 7 3 4 + 0 . 8 5 6 5 7 7 x$ ; $R 2 =$ 0.9979.

# Dilution Verification

A dilution verification study was performed to compare and assess manual dilution and automated (on-board) dilution for Lumipulse G B•R•A•H•M•S PCT. Three specimens (neat, manually diluted 1:10, manually diluted 1:32, automated 1:10) were tested in triplicate. Manual dilutions performed at 1:32 are not recommended for Lumipulse G B·R·A·H·M·S PCT. Automated dilutions for 1:100, 1:200, and 1:1000 on the LUMIPULSE G1200 System can cause erroneous results and should not be used when a specimen exceeds the $1 0 0 ~ \mathrm { { n g / m L } }$ .

Manual dilutions and automated dilutions performed at 1:10 are recommended for Lumipulse G B•R•A•H•M•S PCT.

# Spike and Recovery

Three individual apparently healthy serum samples were spiked and compared to the diluent with the identical concentration. Percent recovery was calculated as follows for individual spiked samples and was found to be within $1 0 0 \pm 1 0 \%$ for all samples tested. See study results in Table 5 below.

$\%$ Recovery $=$ (Mean Measured Natural Test Sample Matrix Concentration $\mathrm { ( n g / m L ) }$ - Endogenous Sample Concentration/Mean Measured Specimen Diluent 1 Concentration (ng/mL)) $\textbf { x l } 0 0 \%$

Table 5: Spike and Recovery.   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Sample ID</td><td rowspan=1 colspan=1>Sample Mean (ng/ml)</td><td rowspan=1 colspan=1>Diluent (ng/ml)</td><td rowspan=1 colspan=1>Recovery (%)</td></tr><tr><td rowspan=10 colspan=1>SerumSample 1</td><td rowspan=1 colspan=1>Endogenous</td><td rowspan=1 colspan=1>0.011</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0.097</td><td rowspan=1 colspan=1>0.091</td><td rowspan=1 colspan=1>95</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0.223</td><td rowspan=1 colspan=1>0.223</td><td rowspan=1 colspan=1>95</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0.445</td><td rowspan=1 colspan=1>0.455</td><td rowspan=1 colspan=1>95</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>1.67</td><td rowspan=1 colspan=1>1.719</td><td rowspan=1 colspan=1>97</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>8.885</td><td rowspan=1 colspan=1>9.073</td><td rowspan=1 colspan=1>98</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>30.317</td><td rowspan=1 colspan=1>31.553</td><td rowspan=1 colspan=1>96</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>44.417</td><td rowspan=1 colspan=1>45.649</td><td rowspan=1 colspan=1>97</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>63.408</td><td rowspan=1 colspan=1>63.252</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>86.949</td><td rowspan=1 colspan=1>82.587</td><td rowspan=1 colspan=1>105</td></tr><tr><td rowspan=10 colspan=1>SerumSample 2</td><td rowspan=1 colspan=1>Endogenous</td><td rowspan=1 colspan=1>0.016</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0.099</td><td rowspan=1 colspan=1>0.091</td><td rowspan=1 colspan=1>91</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0.22</td><td rowspan=1 colspan=1>0.223</td><td rowspan=1 colspan=1>91</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0.433</td><td rowspan=1 colspan=1>0.455</td><td rowspan=1 colspan=1>92</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>1.684</td><td rowspan=1 colspan=1>1.719</td><td rowspan=1 colspan=1>97</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>8.83</td><td rowspan=1 colspan=1>9.073</td><td rowspan=1 colspan=1>97</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>28.963</td><td rowspan=1 colspan=1>31.553</td><td rowspan=1 colspan=1>92</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>45.224</td><td rowspan=1 colspan=1>45.649</td><td rowspan=1 colspan=1>99</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>62.08</td><td rowspan=1 colspan=1>63.252</td><td rowspan=1 colspan=1>98</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>86.22</td><td rowspan=1 colspan=1>82.587</td><td rowspan=1 colspan=1>104</td></tr><tr><td rowspan=10 colspan=1>SerumSample 3</td><td rowspan=1 colspan=1>Endogenous</td><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0.096</td><td rowspan=1 colspan=1>0.091</td><td rowspan=1 colspan=1>97</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0.225</td><td rowspan=1 colspan=1>0.223</td><td rowspan=1 colspan=1>97</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0.44</td><td rowspan=1 colspan=1>0.455</td><td rowspan=1 colspan=1>95</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>1.661</td><td rowspan=1 colspan=1>1.719</td><td rowspan=1 colspan=1>96</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>8.75</td><td rowspan=1 colspan=1>9.073</td><td rowspan=1 colspan=1>96</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>30.363</td><td rowspan=1 colspan=1>31.553</td><td rowspan=1 colspan=1>96</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>45.014</td><td rowspan=1 colspan=1>45.649</td><td rowspan=1 colspan=1>99</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>61.666</td><td rowspan=1 colspan=1>63.252</td><td rowspan=1 colspan=1>97</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>84.661</td><td rowspan=1 colspan=1>82.587</td><td rowspan=1 colspan=1>103</td></tr></table>

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Traceability:

Lumipulse G B∙R∙A∙H∙M∙S PCT values are expressed as $\mathrm { { n g / m L } }$ , and are related to a Fujirebio Inc. maintained reference preparation. The calibrators for the Lumipulse G B∙R∙A∙H∙M∙S PCT product are manufactured gravimetrically and are traceable to B∙R∙A∙H∙M∙S PCT sensitive Kryptor.

Master calibration data is recorded in a two-dimensional bar code on the Lumipulse G B∙R∙A∙H∙M∙S PCT Immunoreaction Cartridge case. The calibration curve is created based on recorded master calibration data and the calibration data. The PCT concentration of a specimen is automatically calculated from the calibration curve. The result of the calculation is reported in $\mathrm { { n g / m L } }$ .

Recalibration is required after a pre-determined calibration interval, when 30 days have elapsed since the previous calibration; quality control results fall out of range or when a new Lumipulse G B∙R∙A∙H∙M∙S PCT Immunoreaction Cartridge lot is loaded.

# Reagent Stability:

The shelf life for Lumipulse G B•R•A•H•M•S PCT Immunoreaction Cartridges and the Lumipulse G B•R•A•H•M•S PCT Calibrators is 6 months at $2 { - } 1 0 ^ { \circ } \mathrm { C }$ . The shelf-life stability protocols and acceptance criteria were reviewed and found to be acceptable.

On-Board Immunoreaction Cartridge Stability Study

The shelf life for Lumipulse G B•R•A•H•M•S PCT Immunoreaction Cartridges is 6 months at $2 { - } 1 0 ^ { \circ } \mathrm { C }$ . The Lumipulse G B•R•A•H•M•S PCT Cartridges can be stored on-board the LUMIPULSE G System for a maximum of 30 days.

On Board Sample Stability Study

A study was performed to establish stability claims for the stability of samples on-board the LUMIPULSE G1200 instrument using Lumipulse G B·R·A·H·M·S PCT. Samples have an onboard stability up to 3 hours.

Reagent Transport Conditions

Lumipulse G B•R•A•H•M•S PCT Immunoreaction Cartridges and the Lumipulse G B•R•A•H•M•S PCT Calibrators are shipped at $2 { \cdot } 1 0 ^ { \circ } \mathrm { C }$ . Materials are shipped to the end user using an insulated container and a predetermined configuration of gel (cold and/or frozen) packs to maintain the product for up to 72 hours when stored at ambient temperature.

# Sample Stability Study

The purpose of this study was to establish the stability of serum and plasma samples for Lumipulse G B·R·A·H·M·S PCT. The following information regarding sample stability are provided in Table 6 and will be included in the final labeling.

Table 6: Sample Stability   

<table><tr><td rowspan=1 colspan=1>Tube</td><td rowspan=1 colspan=1>Condition 1(25° ±2°C)</td><td rowspan=1 colspan=1>Condition 2(2°C-10°)</td><td rowspan=1 colspan=1>Condition 3(25° ±2° *)</td></tr><tr><td rowspan=1 colspan=1>SST</td><td rowspan=1 colspan=1>7 Hours</td><td rowspan=1 colspan=1>2 Days</td><td rowspan=1 colspan=1>3 Hours</td></tr><tr><td rowspan=1 colspan=1>Red Top</td><td rowspan=1 colspan=1>4 Hours</td><td rowspan=1 colspan=1>1 Day</td><td rowspan=1 colspan=1>7 Hours</td></tr><tr><td rowspan=1 colspan=1>KEDTA, LithiumHeparin, SodiumHeparin, and SodiumCitrate</td><td rowspan=1 colspan=1>1 Day</td><td rowspan=1 colspan=1>2 Days</td><td rowspan=1 colspan=1>8 Hours</td></tr></table>

\*Samples were tested after the draw (after introduction of PCT spike) while kept on-the-clot/separator/cells.

# Sample Freeze Thaw Stability Study

A study to establish the maximum number of freeze thaw cycles acceptable for samples being measured by Lumipulse G B·R·A·H·M·S PCT assay was performed. Specimens can be frozen and thawed up to and including 3 freeze thaw cycles for the Lumipulse G B·R·A·H·M·S PCT for the following tube types: SST Serum, Red Top Serum, $\mathrm { K } _ { 2 } \mathrm { E D T A }$ Plasma, Sodium Heparin Plasma, Lithium Heparin Plasma, and Sodium Citrate Plasma.

# d. Detection limit:

The LoB, LoD and LoQ were determined using methods consistent with the guidelines in the CLSI protocol EP17-A2.

The LoB for Lumipulse G B•R•A•H•M•S PCT was $0 . 0 0 9 5 ~ \mathrm { n g / m L }$ . The LoD for Lumipulse G B•R•A•H•M•S PCT on the LUMIPULSE G1200 System was $0 . 0 1 1 4 ~ \mathrm { n g / m L }$ . Seven low level specimens were tested over three days using two LUMIULSE G1200 Systems and two Lumipulse G B•R•A•H•M•S PCT lots for a total of 120 determinations per panel.

The LoQ for Lumipulse G B•R•A•H•M•S PCT on the LUMIPULSE G1200 System was 0.0114 $\mathrm { n g / m L }$ . The $\%$ Total Error (TE), $\%$ bias and $\% \mathrm { C V }$ were calculated:

· $\mathrm { T E } \leq 1 1 . 4 \%$ at $0 . 2 5 ~ \mathrm { { n g / m L } }$ with $a \%$ bias $\leq - 5 . 7 \%$ and a precision $C \mathrm { V } \leq 2 . 8 \%$ . $\mathrm { T E } \leq 1 4 . 1 \%$ at $0 . 1 0 ~ \mathrm { { n g / m L } }$ with a $\%$ bias $\leq - 9 . 2 \%$ and a precision $C V \leq 2 . 5 \%$ .

# e. High Dose Hook Effect

For Lumipulse G B•R•A•H•M•S PCT on the LUMIPULSE G1200 System, no high dose effect was observed for samples containing approximately $1 2 , 0 0 0 ~ \mathrm { n g / m L }$ of PCT.

# f. Analytical specificity:

Interference Testing:

Lumipulse G B•R•A•H•M•S PCT on the LUMIPULSE G1200 System demonstrated an average interference of $\leq 1 0 \%$ (for each compound) in a study consistent with the guidelines in the CLSI Protocol EP7-A2. Human serum specimen pools with procalcitonin concentrations of approximately 0.25 and $2 . 0 \mathrm { n g / m L }$ were supplemented with potentially interfering compounds. The following compounds were tested using Lumipulse G B•R•A•H•M•S PCT and found not to interfere with the assay. See Tables 7 and 8 below.

Table 7: Endogenous Interferents   

<table><tr><td rowspan=1 colspan=1>Endogenous Interferent</td><td rowspan=1 colspan=1>Test Concentration</td></tr><tr><td rowspan=1 colspan=1>Free Bilirubin(unconjugated)</td><td rowspan=1 colspan=1>50 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Conjugated Bilirubin</td><td rowspan=1 colspan=1>50 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>400 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Total Protein (Human Serum Albumin)</td><td rowspan=1 colspan=1>12 g/dL</td></tr><tr><td rowspan=1 colspan=1>Triglycerides (Intralipid 20% Emulsion)</td><td rowspan=1 colspan=1>2500 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Immunoglobulin G (IgG)</td><td rowspan=1 colspan=1>5 g/dL</td></tr><tr><td rowspan=1 colspan=1>Biotin</td><td rowspan=1 colspan=1>19.7 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Human Anti-Mouse Antibodies (HAMA)</td><td rowspan=1 colspan=1>1,000 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Factor (RF)</td><td rowspan=1 colspan=1>1,000 IU/mL</td></tr></table>

Table 8: Exogenous Interferent   

<table><tr><td rowspan=1 colspan=1>Exogenous Interferent</td><td rowspan=1 colspan=1>Concentration(mg/dL)</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>20.01</td></tr><tr><td rowspan=1 colspan=1>Acetylsalicylic Acid</td><td rowspan=1 colspan=1>65.22</td></tr><tr><td rowspan=1 colspan=1>1% Ethanol</td><td rowspan=1 colspan=1>789</td></tr><tr><td rowspan=1 colspan=1>Azithromycin</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Caffeine</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=1 colspan=1>Celecoxib</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>Cetirizine HCl</td><td rowspan=1 colspan=1>0.55</td></tr><tr><td rowspan=1 colspan=1>Dextromethorphan</td><td rowspan=1 colspan=1>0.1</td></tr><tr><td rowspan=1 colspan=1>Dobutamine</td><td rowspan=1 colspan=1>1.13</td></tr><tr><td rowspan=1 colspan=1>Dopamine</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>Doxycycline</td><td rowspan=1 colspan=1>5</td></tr><tr><td rowspan=1 colspan=1>Epinephrine</td><td rowspan=1 colspan=1>0.18</td></tr><tr><td rowspan=1 colspan=1>Furosemide</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Heparin</td><td rowspan=1 colspan=1>8000</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>50.03</td></tr><tr><td rowspan=1 colspan=1>Imipenem</td><td rowspan=1 colspan=1>118</td></tr><tr><td rowspan=1 colspan=1>Levofloxacin</td><td rowspan=1 colspan=1>2.93</td></tr><tr><td rowspan=1 colspan=1>Loratadine</td><td rowspan=1 colspan=1>0.05</td></tr><tr><td rowspan=1 colspan=1>Nicotine</td><td rowspan=1 colspan=1>0.1</td></tr><tr><td rowspan=1 colspan=1>Noradrenaline(norepinephrine)</td><td rowspan=1 colspan=1>0.2</td></tr><tr><td rowspan=1 colspan=1>Oxymetazoline HCl</td><td rowspan=1 colspan=1>0.09</td></tr><tr><td rowspan=1 colspan=1>Phenylephrine</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=1 colspan=1>Prednisolone</td><td rowspan=1 colspan=1>0.3</td></tr><tr><td rowspan=1 colspan=1>Salmeterol</td><td rowspan=1 colspan=1>0.006</td></tr><tr><td rowspan=1 colspan=1>Tiotropium</td><td rowspan=1 colspan=1>0.0022</td></tr><tr><td rowspan=1 colspan=1>Vancomycin</td><td rowspan=1 colspan=1>300</td></tr></table>

# Cross Reactivity:

Lumipulse G B•R•A•H•M•S PCT on the LUMIPULSE G1200 System was evaluated for crossreactivity of the assay with other substances that are similar in structure to PCT in a study consistent with the guidelines in the CLSI Protocol EP7-A2. Human serum specimens with PCT concentrations of approximately 0.1, 0.25, 0.5, 2.0 and $8 0 ~ \mathrm { n g / m L }$ (serum pool 1, 2, 3, 4 and 5, respectively) were supplemented with potentially cross-reacting compounds. The compounds were tested at the concentrations listed below and found to have the following percent cross-reactivity. The $\%$ cross-reactivity for each individual sample was calculated using the following equation. See results in Table 9 below.

$\%$ Cross Reactivity $=$ (Mean Concentration $\operatorname { T e s t }$ $\scriptstyle ( { \mathrm { n g / m L } }$ ) – Mean ConcentrationControl $\mathrm { ( n g / m L ) }$ / Concentration Cross Reactant $\mathrm { ( n g / m L ) }$ ) X 100

Table 9: Cross Reactivity   

<table><tr><td rowspan=1 colspan=1>Interferent</td><td rowspan=1 colspan=1>Sample ID</td><td rowspan=1 colspan=1>Mean TestConcentration(ng/mL) (n=3)</td><td rowspan=1 colspan=1>Mean ControlConcentration(ng/mL) (n=3)</td><td rowspan=1 colspan=1>% CrossReactivity</td></tr><tr><td rowspan=5 colspan=1>HumanCalcitonin10 ng/mL</td><td rowspan=1 colspan=1>Serum Pool 1</td><td rowspan=1 colspan=1>0.113</td><td rowspan=1 colspan=1>0.115</td><td rowspan=1 colspan=1>-0.020%</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 2</td><td rowspan=1 colspan=1>0.263</td><td rowspan=1 colspan=1>0.265</td><td rowspan=1 colspan=1>-0.020%</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 3</td><td rowspan=1 colspan=1>0.537</td><td rowspan=1 colspan=1>0.532</td><td rowspan=1 colspan=1>0.050%</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 4</td><td rowspan=1 colspan=1>2.111</td><td rowspan=1 colspan=1>2.014</td><td rowspan=1 colspan=1>0.970%</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 5</td><td rowspan=1 colspan=1>77.004</td><td rowspan=1 colspan=1>77.275</td><td rowspan=1 colspan=1>-2.710%</td></tr><tr><td rowspan=5 colspan=1>HumanKatacalcin10 ng/mL</td><td rowspan=1 colspan=1>Serum Pool 1</td><td rowspan=1 colspan=1>0.113</td><td rowspan=1 colspan=1>0.116</td><td rowspan=1 colspan=1>-0.030%</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 2</td><td rowspan=1 colspan=1>0.268</td><td rowspan=1 colspan=1>0.266</td><td rowspan=1 colspan=1>0.020%</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 3</td><td rowspan=1 colspan=1>0.537</td><td rowspan=1 colspan=1>0.541</td><td rowspan=1 colspan=1>-0.040%</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 4</td><td rowspan=1 colspan=1>2.118</td><td rowspan=1 colspan=1>2.134</td><td rowspan=1 colspan=1>-0.160%</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 5</td><td rowspan=1 colspan=1>76.476</td><td rowspan=1 colspan=1>76.417</td><td rowspan=1 colspan=1>0.590%</td></tr><tr><td rowspan=5 colspan=1>α-CGRP10,000 ng/mL</td><td rowspan=1 colspan=1>Serum Pool 1</td><td rowspan=1 colspan=1>0.113</td><td rowspan=1 colspan=1>0.113</td><td rowspan=1 colspan=1>0.000%</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 2</td><td rowspan=1 colspan=1>0.261</td><td rowspan=1 colspan=1>0.263</td><td rowspan=1 colspan=1>0.000%</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 3</td><td rowspan=1 colspan=1>0.525</td><td rowspan=1 colspan=1>0.530</td><td rowspan=1 colspan=1>0.000%</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 4</td><td rowspan=1 colspan=1>2.126</td><td rowspan=1 colspan=1>2.131</td><td rowspan=1 colspan=1>0.000%</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 5</td><td rowspan=1 colspan=1>78.339</td><td rowspan=1 colspan=1>77.526</td><td rowspan=1 colspan=1>0.008%</td></tr><tr><td rowspan=5 colspan=1>β-CGRP10,000 ng/mL</td><td rowspan=1 colspan=1>Serum Pool 1</td><td rowspan=1 colspan=1>0.117</td><td rowspan=1 colspan=1>0.115</td><td rowspan=1 colspan=1>0.000%</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 2</td><td rowspan=1 colspan=1>0.269</td><td rowspan=1 colspan=1>0.265</td><td rowspan=1 colspan=1>0.000%</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 3</td><td rowspan=1 colspan=1>0.540</td><td rowspan=1 colspan=1>0.534</td><td rowspan=1 colspan=1>0.000%</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 4</td><td rowspan=1 colspan=1>2.173</td><td rowspan=1 colspan=1>2.175</td><td rowspan=1 colspan=1>0.000%</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 5</td><td rowspan=1 colspan=1>77.705</td><td rowspan=1 colspan=1>77.443</td><td rowspan=1 colspan=1>0.003%</td></tr><tr><td rowspan=5 colspan=1>SalmonCalcitonin13.2 μg/mL</td><td rowspan=1 colspan=1>Serum Pool 1</td><td rowspan=1 colspan=1>0.116</td><td rowspan=1 colspan=1>0.111</td><td rowspan=1 colspan=1>0.000%</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 2</td><td rowspan=1 colspan=1>0.265</td><td rowspan=1 colspan=1>0.272</td><td rowspan=1 colspan=1>0.000%</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 3</td><td rowspan=1 colspan=1>0.537</td><td rowspan=1 colspan=1>0.537</td><td rowspan=1 colspan=1>0.000%</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 4</td><td rowspan=1 colspan=1>2.185</td><td rowspan=1 colspan=1>2.157</td><td rowspan=1 colspan=1>0.000%</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 5</td><td rowspan=1 colspan=1>77.137</td><td rowspan=1 colspan=1>77.801</td><td rowspan=1 colspan=1>-0.005%</td></tr><tr><td rowspan=5 colspan=1>EelCalcitonin7.5 μg/mL</td><td rowspan=1 colspan=1>Serum Pool 1</td><td rowspan=1 colspan=1>0.115</td><td rowspan=1 colspan=1>0.114</td><td rowspan=1 colspan=1>0.000%</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 2</td><td rowspan=1 colspan=1>0.264</td><td rowspan=1 colspan=1>0.263</td><td rowspan=1 colspan=1>0.000%</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 3</td><td rowspan=1 colspan=1>0.542</td><td rowspan=1 colspan=1>0.525</td><td rowspan=1 colspan=1>0.000%</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 4</td><td rowspan=1 colspan=1>2.172</td><td rowspan=1 colspan=1>2.141</td><td rowspan=1 colspan=1>0.000%</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 5</td><td rowspan=1 colspan=1>77.631</td><td rowspan=1 colspan=1>78.072</td><td rowspan=1 colspan=1>-0.006%</td></tr></table>

f. Assay cut-off: See clinical cut-off

2. Comparison studies:

a. Method comparison with predicate device:

The Lumipulse G B•R•A•H•M•S PCT method comparison was performed on the LUMIPULSE G1200 System in a study consistent with the guidelines in CLSI Protocol EP09-A3C.

B•R•A•H•M•S PCT sensitive KRYPTOR testing was performed following the appropriate QC procedures and manufacturer’s instruction specified in the B•R•A•H•M•S PCT sensitive KRYPTOR package insert.

Sample testing with Lumipulse G B•R•A•H•M•S PCT was performed on three LUMIPULSE G1200 Systems utilizing two lots of ICs, one lot of calibrators, and four calibrator curves. There were 102 samples from female subjects $( 4 5 . 7 \% )$ and 121 samples from male subjects $( 5 4 . 3 \% )$ in the method comparison sample set. The PCT range of samples tested and age demographics are found in Tables 10 and 11 below.

Table 10: Total Samples per Specified Lumipulse G B•R•A•H•M•S PCT Ranges   

<table><tr><td rowspan=1 colspan=1>Lumipulse G B•R•A•H•M•S PCT Number of SamplesRanges</td><td rowspan=1 colspan=1>Number of Samples</td></tr><tr><td rowspan=1 colspan=1>0.000-0.250 ng/mL</td><td rowspan=1 colspan=1>53</td></tr><tr><td rowspan=1 colspan=1>0.251-0.500ng/mL</td><td rowspan=1 colspan=1>35</td></tr><tr><td rowspan=1 colspan=1>0.501-2.000 ng/mL</td><td rowspan=1 colspan=1>47</td></tr><tr><td rowspan=1 colspan=1>2.001-10.000 ng/mL</td><td rowspan=1 colspan=1>32</td></tr><tr><td rowspan=1 colspan=1>10.001-20.000 ng/mL</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>20.001-50.000 ng/mL</td><td rowspan=1 colspan=1>27</td></tr><tr><td rowspan=1 colspan=1>50.001-100.000 ng/mL</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>100.001-250.000 ng/mL</td><td rowspan=1 colspan=1>7</td></tr><tr><td rowspan=1 colspan=1>250.001-1000.000 ng/mL</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>TOTAL</td><td rowspan=1 colspan=1>223</td></tr></table>

Table 11: Summary of Age Demographics for Evaluable Subjects   

<table><tr><td rowspan=1 colspan=1>Age Group(years)</td><td rowspan=1 colspan=1>EvaluableSubjects</td></tr><tr><td rowspan=1 colspan=1>22-29</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>30-39</td><td rowspan=1 colspan=1>9</td></tr><tr><td rowspan=1 colspan=1>40-49</td><td rowspan=1 colspan=1>14</td></tr><tr><td rowspan=1 colspan=1>50-59</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=1 colspan=1>60-69</td><td rowspan=1 colspan=1>63</td></tr><tr><td rowspan=1 colspan=1>70-79</td><td rowspan=1 colspan=1>52</td></tr><tr><td rowspan=1 colspan=1>80-89</td><td rowspan=1 colspan=1>44</td></tr><tr><td rowspan=1 colspan=1>90-99</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>223</td></tr><tr><td rowspan=1 colspan=1>Mean Age</td><td rowspan=1 colspan=1>69.3</td></tr><tr><td rowspan=1 colspan=1>Median Age</td><td rowspan=1 colspan=1>70.0</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation (SD) (years)</td><td rowspan=1 colspan=1>14.9</td></tr><tr><td rowspan=1 colspan=1>Minimum Age</td><td rowspan=1 colspan=1>26</td></tr><tr><td rowspan=1 colspan=1>Maximum Age</td><td rowspan=1 colspan=1>98</td></tr></table>

Two separate analysis of the study data were performed, one with analysis restricted to samples with B•R•A•H•M•S PCT sensitive KRYPTOR assays no more than $5 0 . 0 \mathrm { n g / m L }$ and one with an extended analysis including all samples tested. Weighted Deming and Passing-Bablok regressions were performed with slope, correlation coefficient, intercept and mean difference along with $9 5 \%$ CIs determined and found to be acceptable. Bland-Altman Plots with mean $\%$ difference, percent limits of agreement and $9 5 \%$ CIs for Lumipulse G PCT and the predicate with B•R•A•H•M•S PCT sensitive KRYPTOR were also calculated and found to be acceptable.

207 were samples tested with Lumipulse G B•R•A•H•M•S PCT had results ranging from $0 . 0 5 4 \mathrm { - } 5 8 . 1 5 6 ~ \mathrm { n g / m L }$ with B•R•A•H•M•S PCT sensitive KRYPTOR results for these same samples ranged from $0 . 0 2 4 { - } 4 8 . 4 3 0 \mathrm { n g / m L }$ . Weighted Deming Regression results are found in Table 12. The clinical bias and confidence intervals (CIs) at the clinical decision points are listed in Table 13.

Table 12: Weighted Deming Regression for Lumipulse G B•R•A•H•M•S PCT when compared to B•R•A•H•M•S PCT sensitive KRYPTOR (measurement range $0 . 0 2 0 { - } 5 0 . 0 0 0 ~ \mathrm { n g / m L ) }$   

<table><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>CorrelationCoefficient (r)</td><td rowspan=1 colspan=1>Intercept (95% CI)</td><td rowspan=1 colspan=1>Slope (95% CI)</td><td rowspan=1 colspan=1>MeanDifference(ng/mL)</td></tr><tr><td rowspan=1 colspan=1>207</td><td rowspan=1 colspan=1>0.9535</td><td rowspan=1 colspan=1>-0.0044(-0.0223, 0.0135)</td><td rowspan=1 colspan=1>1.0199(0.9633, 1.0765)</td><td rowspan=1 colspan=1>0.185</td></tr></table>

Table 13: Clinical bias and CIs at the clinical decision points   

<table><tr><td rowspan=1 colspan=1>Clinical Decision Point(ng/mL)</td><td rowspan=1 colspan=1>Bias(ng/mL)</td><td rowspan=1 colspan=1>Lower CI</td><td rowspan=1 colspan=1>Upper CI</td></tr><tr><td rowspan=1 colspan=1>0.100</td><td rowspan=1 colspan=1>-0.0031</td><td rowspan=1 colspan=1>-0.0180</td><td rowspan=1 colspan=1>0.0117</td></tr><tr><td rowspan=1 colspan=1>0.250</td><td rowspan=1 colspan=1>-0.0009</td><td rowspan=1 colspan=1>-0.0148</td><td rowspan=1 colspan=1>0.0130</td></tr><tr><td rowspan=1 colspan=1>0.500</td><td rowspan=1 colspan=1>0.0027</td><td rowspan=1 colspan=1>-0.0185</td><td rowspan=1 colspan=1>0.0239</td></tr><tr><td rowspan=1 colspan=1>2.000</td><td rowspan=1 colspan=1>0.0246</td><td rowspan=1 colspan=1>-0.0749</td><td rowspan=1 colspan=1>0.1242</td></tr></table>

From the total 207 individual lithium heparin plasma samples tested, the percent agreement between the Lumipulse G B•R•A•H•M•S PCT and B•R•A•H•M•S PCT sensitive KRYPTOR at cut-off $0 . 5 0 0 ~ \mathrm { n g / m L }$ was determined. See Table 14 for $2 \times 2$ summary table.

• Negative percent agreement (NPA): $9 5 . 5 \%$ (84/88), $9 5 \%$ CI: $8 8 . 9 \%$ , $9 8 . 2 \%$ • Positive percent agreement (PPA): $9 6 . 6 \%$ (115/119), $9 5 \%$ CI: $9 1 . 7 \%$ , $9 8 . 7 \%$

Table 14: Lumipulse G B•R•A•H•M•S PCT vs. B•R•A•H•M•S PCT sensitive KRYPTOR at $\underline { { 0 . 5 0 0 ~ \mathrm { n g / m L } } }$ cut-off   

<table><tr><td rowspan=2 colspan=1>B•R•A•H·M•S PCT sensitive KRYPTOR(ng/mL)</td><td rowspan=1 colspan=3>Lumipulse G B•R•A•H•M•S PCT(ng/mL)</td></tr><tr><td rowspan=1 colspan=1>≤0.500</td><td rowspan=1 colspan=1>&gt;0.500</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>≤0.500</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>88</td></tr><tr><td rowspan=1 colspan=1>&gt;0.500</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>115</td><td rowspan=1 colspan=1>119</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>119</td><td rowspan=1 colspan=1>207</td></tr></table>

From the total 207 individual lithium heparin plasma samples tested, the percent agreement between the Lumipulse G B•R•A•H•M•S PCT and B•R•A•H•M•S PCT sensitive KRYPTOR at cut-off $2 . 0 0 0 ~ \mathrm { { n g / m L } }$ was determined. See Table 15, 16 and 18 for 2 x 2, $3 \mathrm { ~ x ~ } 3$ summary and regression analyses, respectively. Additionally, Table 17 presents a cross-tabulation of all samples within each medical decision point range.

• NPA: $9 9 . 2 \%$ (132/133), $9 5 \%$ CI: $9 5 . 9 \%$ , $9 9 . 9 \%$ • PPA: $9 5 . 9 \%$ (71/74), $9 5 \%$ CI: $8 8 . 7 \%$ , $9 8 . 6 \%$

Table 15: Lumipulse G B•R•A•H•M•S PCT vs. B•R•A•H•M•S PCT sensitive KRYPTOR at $2 . 0 0 0 \mathrm { n g / m L }$ cut-off   

<table><tr><td rowspan=2 colspan=1>B·R•A·H•M•S PCTsensitive KRYPTOR(ng/mL)</td><td rowspan=1 colspan=3>Lumipulse G B•R•A•H•M•S PCT(ng/mL)</td></tr><tr><td rowspan=1 colspan=1>≤2.000</td><td rowspan=1 colspan=1>&gt;2.000</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>≤2.000</td><td rowspan=1 colspan=1>132</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>133</td></tr><tr><td rowspan=1 colspan=1>&gt;2.000</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>74</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>135</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>207</td></tr></table>

Table $1 6 \colon 3 \mathrm { x } 3 $ Table: Lumipulse G B•R•A•H•M•S PCT vs. B•R•A•H•M•S PCT sensitive KRYPTOR   

<table><tr><td rowspan=2 colspan=1>B•R·A·H•M•S PCTsensitive KRYPTOR(ng/mL)</td><td rowspan=1 colspan=4>Lumipulse G B•R•A•H•M•S PCT(ng/mL)</td></tr><tr><td rowspan=1 colspan=1>≤0.500</td><td rowspan=1 colspan=1>0.501&lt;PCT≤2.000</td><td rowspan=1 colspan=1>&gt;2.000</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>0.500</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>88</td></tr><tr><td rowspan=1 colspan=1>0.501&lt;PCT≤2.000</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>45</td></tr><tr><td rowspan=1 colspan=1>&gt;2.000</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>74</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>207</td></tr></table>

Table 17: Cross Tabulation of all Samples $( \mathrm { n } { = } 2 0 7 )$ ) within each Medical Decision Point Range   

<table><tr><td rowspan=2 colspan=1>B•R•A·H·M•SPCT sensitiveKRYPTOR(ng/m)L</td><td rowspan=1 colspan=5>Lumipulse G PCT (ng/mL)</td></tr><tr><td rowspan=1 colspan=1>0.0237-0.100</td><td rowspan=1 colspan=1>0.101-0.250</td><td rowspan=1 colspan=1>0.251-0.500</td><td rowspan=1 colspan=1>0.501-2.000</td><td rowspan=1 colspan=1>2.001-58.200</td></tr><tr><td rowspan=1 colspan=1>0.0237-0.100</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>0.101-0.250</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>0.251-0.500</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>0.501-2.000</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>2.001-58.200</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>71</td></tr></table>

Table 18: Regression Analyses $\mathrm { ( N } { = } 2 0 7 \mathrm { ) }$   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>Estimate</td><td rowspan=1 colspan=1>Lower CI</td><td rowspan=1 colspan=1>Upper CI</td></tr><tr><td rowspan=2 colspan=1>Weighted Deming</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>-0.0044</td><td rowspan=1 colspan=1>-0.0223</td><td rowspan=1 colspan=1>0.0135</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>1.0199</td><td rowspan=1 colspan=1>0.9633</td><td rowspan=1 colspan=1>1.0765</td></tr><tr><td rowspan=2 colspan=1>Passing- Bablok</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>-0.007</td><td rowspan=1 colspan=1>-0.025</td><td rowspan=1 colspan=1>0.004</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>1.000</td><td rowspan=1 colspan=1>0.981</td><td rowspan=1 colspan=1>1.038</td></tr></table>

223 samples tested with Lumipulse G B•R•A•H•M•S PCT had results ranging from 0.054- $3 4 8 . 9 4 0 ~ \mathrm { n g / m L }$ and B•R•A•H•M•S PCT sensitive KRYPTOR results for these same samples ranged from $0 . 0 2 4 { - } 3 4 5 . 9 0 0 \mathrm { n g / m L }$ . Weighted Deming Regression results are found in Table 19. The clinical bias and CIs at the clinical decision points were determined. No evidence of bias was found at the medical decision points. (See results in Table 20.)

Table 19: Weighted Deming Regression for Lumipulse G B•R•A•H•M•S PCT when compared to B•R•A•H•M•S PCT sensitive KRYPTOR (measurement range $> 0 . 0 2 0 ~ \mathrm { n g / m L } )$   

<table><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>CorrelationCoefficient (r)</td><td rowspan=1 colspan=1>Intercept (95% CI)</td><td rowspan=1 colspan=1>Slope (95% CI)</td><td rowspan=1 colspan=1>MeanDifference(ng/mL)</td><td rowspan=1 colspan=1>Percentdifference mean</td></tr><tr><td rowspan=1 colspan=1>223</td><td rowspan=1 colspan=1>0.9846</td><td rowspan=1 colspan=1>-0.0025(-0.0195, 0.0145)</td><td rowspan=1 colspan=1>1.0103(0.9601, 1.0605)</td><td rowspan=1 colspan=1>-0.232</td><td rowspan=1 colspan=1>6.8%</td></tr></table>

Table 20: Bias at Clinical Decision Points   

<table><tr><td rowspan=1 colspan=1>Clinical Decision Point(ng/mL)</td><td rowspan=1 colspan=1>Bias</td><td rowspan=1 colspan=1>Lower CI</td><td rowspan=1 colspan=1>Upper CI</td></tr><tr><td rowspan=1 colspan=1>0.100</td><td rowspan=1 colspan=1>-0.0022</td><td rowspan=1 colspan=1>-0.0167</td><td rowspan=1 colspan=1>0.0122</td></tr><tr><td rowspan=1 colspan=1>0.250</td><td rowspan=1 colspan=1>-0.0014</td><td rowspan=1 colspan=1>-0.0151</td><td rowspan=1 colspan=1>0.0124</td></tr><tr><td rowspan=1 colspan=1>0.500</td><td rowspan=1 colspan=1>0.0001</td><td rowspan=1 colspan=1>-0.0198</td><td rowspan=1 colspan=1>0.0199</td></tr><tr><td rowspan=1 colspan=1>2.000</td><td rowspan=1 colspan=1>0.0087</td><td rowspan=1 colspan=1>-0.0800</td><td rowspan=1 colspan=1>0.0975</td></tr></table>

Data was analyzed for concordance at the $0 . 5 0 0 ~ \mathrm { n g / m L }$ cut-off. (See Table 21 for $2 \times 2$ summary.) The percent agreement between the Lumipulse G B•R•A•H•M•S PCT and B•R•A•H•M•S PCT sensitive KRYPTOR at cut-off $0 . 5 0 0 ~ \mathrm { n g / m L }$ for the 223-individual lithium heparin plasma samples tested was determined:

• NPA: $9 5 . 5 \%$ (84/88), $9 5 \%$ CI: $8 8 . 9 \%$ , $9 8 . 2 \%$ • PPA: $9 7 . 0 \%$ (131/135), $9 5 \%$ CI: $9 2 . 6 \%$ , $9 8 . 8 \%$

Table 21: Lumipulse G B•R•A•H•M•S PCT vs. B•R•A•H•M•S PCT sensitive KRYPTOR at cut-off $0 . 5 0 0 ~ \mathrm { n g / m L }$   

<table><tr><td rowspan=2 colspan=1>BR•A·H·M•S PCTsensitive KRYPTOR(ng/mL)</td><td rowspan=1 colspan=3>Lumipulse G B•R•A•H•M•S PCT(ng/mL)</td></tr><tr><td rowspan=1 colspan=1>≤0.500</td><td rowspan=1 colspan=1>&gt;0.500</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>≤0.500</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>88</td></tr><tr><td rowspan=1 colspan=1>&gt;0.500</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>131</td><td rowspan=1 colspan=1>135</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>135</td><td rowspan=1 colspan=1>223</td></tr></table>

Data was analyzed for concordance at the $2 . 0 0 0 ~ \mathrm { { n g / m L } }$ cut-off. The percent agreement between the Lumipulse G B•R•A•H•M•S PCT and B•R•A•H•M•S PCT sensitive KRYPTOR at cut-off $2 . 0 0 0 ~ \mathrm { { n g / m L } }$ for the 223-individual lithium heparin plasma samples tested was determined. See Table 22, 23 and 25 for $2 \times 2$ , $3 \mathrm { ~ x ~ } 3$ summary tables and regression analyses, respectively. Additionally, Table 24 presents a cross-tabulation of all samples within each medical decision point range

Table 22: Lumipulse G B•R•A•H•M•S PCT vs. B•R•A•H•M•S PCT sensitive KRYPTOR at cut-off $2 . 0 0 0 \mathrm { n g / m L }$ .   

<table><tr><td rowspan=2 colspan=1>B•R•A·H·M•S PCTsensitive KRYPTOR(ng/mL)</td><td rowspan=1 colspan=3>Lumipulse G B•R•A•H•M•S PCT(ng/mL)</td></tr><tr><td rowspan=1 colspan=1>≤2.000</td><td rowspan=1 colspan=1>&gt;2.000</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>≤2.000</td><td rowspan=1 colspan=1>132</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>133</td></tr><tr><td rowspan=1 colspan=1>&gt;2.000</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>90</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>135</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>223</td></tr></table>

Table $2 3 \colon 3 \mathrm { x } 3 $ Table: Lumipulse G B•R•A•H•M•S PCT vs. B•R•A•H•M•S PCT sensitive KRYPTOR   
Table 24: Cross Tabulation of all Samples $\mathrm { ( n { = } } 2 2 3$ ) within each Medical Decision Point Range   

<table><tr><td rowspan=2 colspan=1>B•R•A·H·M•S PCTsensitive KRYPTOR(ng/mL)</td><td rowspan=1 colspan=4>Lumipulse G B•R•A•H•M·S PCT(ng/mL)</td></tr><tr><td rowspan=1 colspan=1>≤2.000</td><td rowspan=1 colspan=1>0.501&lt;PCT≤2.000</td><td rowspan=1 colspan=1>&gt;2.000</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>≤2.000</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>88</td></tr><tr><td rowspan=1 colspan=1>0.501&lt;PCT≤2.000</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>45</td></tr><tr><td rowspan=1 colspan=1>&gt;2.000</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>90</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>223</td></tr></table>

<table><tr><td rowspan=2 colspan=1>B·R·A·H·M•SPCT sensitiveKRYPTOR(ng/mL)</td><td rowspan=1 colspan=5>Lumipulse G PCT (ng/mL)</td></tr><tr><td rowspan=1 colspan=1>0.0237-0.100</td><td rowspan=1 colspan=1>0.101-0.250</td><td rowspan=1 colspan=1>0.251-0.500</td><td rowspan=1 colspan=1>0.501-2.000</td><td rowspan=1 colspan=1>2.001-58.200</td></tr><tr><td rowspan=1 colspan=1>0.0237-0.100</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>0.101-0.250</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>0.251-0.500</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>0.501-2.000</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>2.001-58.200</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>87</td></tr></table>

Table 25: Regression Analyses $\scriptstyle ( \mathrm { N } = 2 2 3$ )   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>Estimate</td><td rowspan=1 colspan=1>Lower CI</td><td rowspan=1 colspan=1>Upper CI</td></tr><tr><td rowspan=2 colspan=1>WeightedDeming</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>-0.0025</td><td rowspan=1 colspan=1>-0.0195</td><td rowspan=1 colspan=1>0.0145</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>1.0103</td><td rowspan=1 colspan=1>0.9601</td><td rowspan=1 colspan=1>1.0605</td></tr><tr><td rowspan=2 colspan=1>Passing-Bablok</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>-0.005</td><td rowspan=1 colspan=1>-0.017</td><td rowspan=1 colspan=1>0.006</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>0.995</td><td rowspan=1 colspan=1>0.977</td><td rowspan=1 colspan=1>1.013</td></tr></table>

# b. Matrix comparison (Specimen Tube Type Study):

The Lumipulse G B•R•A•H•M•S PCT matrix comparison study was performed to evaluate the difference across tube types (SST, $\mathrm { K } _ { 2 } \mathrm { E D T A }$ , Lithium Heparin, Sodium Heparin, and Sodium Citrate) versus the means of the control samples (Red top serum) analyzed per CLSI guideline EP9-A3. Donor blood was drawn into 78 matched sets of collection tubes. The slope for each tube type when compared to the control had $9 5 \%$ confidence intervals that lay entirely within the range 0.9 to 1.1 and the correlation coefficients were $\geq 0 . 9$ . Results are summarized in Table 26 below.

Table 26: Weighted Deming Regression Analysis Summary of Different Tube Type versus Red Top Tubes   

<table><tr><td rowspan=2 colspan=1>Tube Type</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=2>ConcentrationRange (ng/mL)</td><td rowspan=1 colspan=3>Slope</td><td rowspan=1 colspan=3>Intercept</td><td rowspan=2 colspan=1>PearsonCorrelationCoefficient</td></tr><tr><td rowspan=1 colspan=1>Min</td><td rowspan=1 colspan=1>Max</td><td rowspan=1 colspan=1>Estimate</td><td rowspan=1 colspan=1>Lower95%CI</td><td rowspan=1 colspan=1>Upper95%CI</td><td rowspan=1 colspan=1>Estimate</td><td rowspan=1 colspan=1>Lower95%CI</td><td rowspan=1 colspan=1>Upper95% CI</td></tr><tr><td rowspan=1 colspan=1>SST</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>0.014</td><td rowspan=1 colspan=1>83.435</td><td rowspan=1 colspan=1>1.0023</td><td rowspan=1 colspan=1>0.9800</td><td rowspan=1 colspan=1>1.0246</td><td rowspan=1 colspan=1>-0.0081</td><td rowspan=1 colspan=1>-0.0191</td><td rowspan=1 colspan=1>0.0029</td><td rowspan=1 colspan=1>0.9968</td></tr><tr><td rowspan=1 colspan=1>K2EDTA</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>0.015</td><td rowspan=1 colspan=1>77.148</td><td rowspan=1 colspan=1>1.0208</td><td rowspan=1 colspan=1>1.0002</td><td rowspan=1 colspan=1>1.0414</td><td rowspan=1 colspan=1>-0.0077</td><td rowspan=1 colspan=1>-0.0190</td><td rowspan=1 colspan=1>0.0036</td><td rowspan=1 colspan=1>0.9973</td></tr><tr><td rowspan=1 colspan=1>Li Heparin</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>0.014</td><td rowspan=1 colspan=1>83.076</td><td rowspan=1 colspan=1>1.0010</td><td rowspan=1 colspan=1>0.9560</td><td rowspan=1 colspan=1>1.0459</td><td rowspan=1 colspan=1>0.0018</td><td rowspan=1 colspan=1>- 0.0121</td><td rowspan=1 colspan=1>0.0086</td><td rowspan=1 colspan=1>0.9961</td></tr><tr><td rowspan=1 colspan=1>Na Heparin</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>0.015</td><td rowspan=1 colspan=1>79.150</td><td rowspan=1 colspan=1>1.0264</td><td rowspan=1 colspan=1>1.0070</td><td rowspan=1 colspan=1>1.0458</td><td rowspan=1 colspan=1>-0.0049</td><td rowspan=1 colspan=1>-0.0200</td><td rowspan=1 colspan=1>0.0101</td><td rowspan=1 colspan=1>0.9983</td></tr><tr><td rowspan=1 colspan=1>Citrate</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>0.013</td><td rowspan=1 colspan=1>87.614</td><td rowspan=1 colspan=1>1.0399</td><td rowspan=1 colspan=1>1.0171</td><td rowspan=1 colspan=1>1.0626</td><td rowspan=1 colspan=1>-0.0095</td><td rowspan=1 colspan=1>-0.0218</td><td rowspan=1 colspan=1>0.0028</td><td rowspan=1 colspan=1>0.9963</td></tr></table>

3. Clinical studies:

a. Clinical Sensitivity: Not applicable.   
b. Clinical specificity: Not applicable   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-offs: 28-day mortality:

$\Delta \mathbf { P C T } \leq 8 0 \%$

A decrease in the PCT levels below or equal to $80 \%$ defines a positive ΔPCT test result representing a higher risk for 28-day all-cause mortality of patients diagnosed with severe sepsis or septic shock.

# $\Delta \mathbf { P C T } > 8 0 \%$

A decrease in the PCT levels of more than $80 \%$ defines a negative ΔPCT test result representing a lower risk for 28-day all-cause mortality of patients diagnosed with severe sepsis or septic shock.

# Progression Risk:

$\mathbf { P C T } > 2 \ \mathbf { n g } / \mathbf { m L }$ : A PCT level above $2 . 0 \ : \mathrm { n g / m L }$ on the first day of ICU admission is associated with a high risk for progression to severe sepsis and/or septic shock. $\mathbf { P C T < 0 . 5 \ n g / m L }$ : A PCT level below $0 . 5 ~ \mathrm { { n g / m L } }$ on the first day of ICU admission is associated with a low risk for progression to severe sepsis and/or septic shock.

LRTI Antibiotic Decision Making:

· $\mathbf { P C T < 0 . 1 0 \ n g / m L }$ : Antibiotic therapy strongly discouraged.

· PCT $\mathbf { 0 . 1 0 { - } 0 . 2 5 \ n g / m L }$ : Antibiotic therapy discouraged. · PCT $\mathbf { 0 . 2 6 { - 0 . 5 0 } \ n g / m L }$ : Antibiotic therapy encouraged. · PCT $\mathrm { > } 0 . 5 0 \ \mathrm { n g / m L }$ : Antibiotic therapy strongly encouraged. · $\mathbf { P C T \le 0 . 2 5 \ n g / m L }$ : Antibiotic therapy may be discontinued $\Delta \mathbf { P C T } > 8 0 \%$ : Antibiotic therapy may be discontinued

Sepsis Antibiotic Discontinuation:

$\Delta \mathbf { P C T } > 8 0 \%$ : Antibiotic therapy may be discontinued $\mathbf { P C T \leq 0 . 5 0 \ n g / m L }$ : Antibiotic therapy may be discontinued

The LUMIPULSE PCT Change Calculator, for use with calculations for assessing Cumulative 28- day Risk of All-Cause Mortality, Initiation and Discontinuation, is a web-based software that will be published on the sponsor’s controlled website and made available to end users via the Internet by entering the following URL (www.fujirebio-pct-calculator.com). The calculator software is validated for use on Microsoft Internet Explorer, Google Chrome, Mozilla Firefox, Apple Safari.

# 5. Expected values/Reference range:

Results from a total of 213 samples were used to determine the distribution of Lumipulse G B•R•A•H•M•S PCT results in apparently healthy individuals. Subject demographics for age are presented in Table 27 and subject demographics for race are presented in Table 28 for the apparently healthy subjects. Descriptive statistics for the Lumipulse G B•R•A•H•M•S PCT results are presented in Table 29 for the apparently healthy subjects.

Table 27: Summary of Age Demographics for Healthy Subjects   

<table><tr><td rowspan=1 colspan=1>Age Group (years)</td><td rowspan=1 colspan=1>ApparentlyHealthy(All)</td><td rowspan=1 colspan=1>ApparentlyHealthy(Females)</td><td rowspan=1 colspan=1>ApparentlyHealthy (Males)</td></tr><tr><td rowspan=1 colspan=1>22-29</td><td rowspan=1 colspan=1>73</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>35</td></tr><tr><td rowspan=1 colspan=1>30-39</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>32</td></tr><tr><td rowspan=1 colspan=1>40-49</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>31</td></tr><tr><td rowspan=1 colspan=1>.50-59</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>12</td></tr><tr><td rowspan=1 colspan=1>60-69</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>≥ 70</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Unknown</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>213</td><td rowspan=1 colspan=1>101</td><td rowspan=1 colspan=1>112</td></tr><tr><td rowspan=1 colspan=1>Mean Age (years)</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>37</td></tr><tr><td rowspan=1 colspan=1>Median Age (years)</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>36</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation(SD) (years)</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>Minimum Age (years)</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22</td></tr><tr><td rowspan=1 colspan=1>Maximum Age (years)</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>68</td></tr></table>

Table 28: Summary of Race and Ethnicity Demographics for Healthy Subjects   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>ApparentlyHealthy(All)</td><td rowspan=1 colspan=1>ApparentlyHealthy(Females)</td><td rowspan=1 colspan=1>ApparentlyHealthy (Males)</td></tr><tr><td rowspan=1 colspan=1>White</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>42</td></tr><tr><td rowspan=1 colspan=1>Black/AfricanAmerican</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>22</td></tr><tr><td rowspan=1 colspan=1>Hispanic</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>Asian/Pacific Islander</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Other</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Unknown</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>213</td><td rowspan=1 colspan=1>101</td><td rowspan=1 colspan=1>112</td></tr></table>

To determine the upper limit of normal for the Lumipulse G B•R•A•H•M•S PCT assay, calculations of the $9 5 \%$ reference interval were performed for the overall set of apparently healthy females, apparently healthy males, and combined apparently healthy females and males in the study according to CLSI EP28-A3. These results are presented in Table 29 below.

Table 29: Lumipulse G B•R•A•H•M•S PCT Summary of $9 5 \%$ Reference Interval for Apparently Healthy Females, Apparently Healthy Males and Combined Apparently Healthy Females and Males   

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=3>Cohort</td></tr><tr><td rowspan=1 colspan=1>Apparently Healthy(All)</td><td rowspan=1 colspan=1>Apparently Healthy(Females)</td><td rowspan=1 colspan=1>Apparently Healthy(Males)</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>213</td><td rowspan=1 colspan=1>101</td><td rowspan=1 colspan=1>112</td></tr><tr><td rowspan=1 colspan=1>95% ReferenceInterval (ng/mL)</td><td rowspan=1 colspan=1>0.003 - 0.045</td><td rowspan=1 colspan=1>0.003 - 0.029</td><td rowspan=1 colspan=1>0.004 - 0.045</td></tr><tr><td rowspan=1 colspan=1>Lower 95%Reference Limit(90% ConfidenceInterval [CI])(ng/mL)</td><td rowspan=1 colspan=1>0.003 (0.002 - 0.004)</td><td rowspan=1 colspan=1>0.003 (0.002 - 0.004)</td><td rowspan=1 colspan=1>0.004 (0.002 - 0.005)</td></tr><tr><td rowspan=1 colspan=1>Upper 95%Reference Limit(90% CI) (ng/mL)</td><td rowspan=1 colspan=1>0.045 (0.030 - 0.068)</td><td rowspan=1 colspan=1>0.029 (0.017 - 0.065)</td><td rowspan=1 colspan=1>0.045 (0.037 - 0.103)</td></tr></table>

Overall, $9 8 . 1 \%$ (209/213) of the apparently healthy subjects had a Lumipulse G B•R•A•H•M•S PCT value equal to or below $0 . 0 4 5 ~ \mathrm { n g / m L }$ . In a population of 213 self-reported healthy individuals, the 95th percentile, upper reference range limit was calculated at $0 . 0 4 5 ~ \mathrm { n g / m L }$ .

It is recommended that each laboratory establish its own range, which may be unique to the population it serves depending upon geographical, patient, and environmental factors.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Parts 801 and 809, as applicable and the special controls for this device type under 21 CFR 866.3215.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.